However, epigenetic therapy (e.g., DNMT1 and HDAC inhibitors) can generate tumor-specific transposable element-derived antigens in glioblastoma but also activate transposable elements in normal cells, requiring careful prioritization of candidate antigens and perhaps using cancer cell-specific agents to create tumor-enriched antigens in glioblastoma cells ex vivo as OVs may offer a strategy that eliminates normal cell response (157, 160). This evidence concerns the gene DNMT1 and glioblastoma.